Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis

References

• Cortes J, Pavlovsky C, Saußele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914–1926. doi:10.1016/S0140-6736(21)01204-6.
   PubMed Web of Science ®Google Scholar
• Radich JP, Deininger M, Abboud CN, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(9):1108–1135. doi:10.6004/jnccn.2018.0071.
   PubMed Web of Science ®Google Scholar
• Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021;49:100825. doi:10.1016/j.blre.2021.100825.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2.
   PubMed Web of Science ®Google Scholar
• Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, et al. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia—What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968. doi:10.1016/j.blre.2022.100968.
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, Sweet K, Emole J, et al. Long-term BCR-ABL1 tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Anticancer Res. 2015;35(12):6355–6364.
   PubMed Web of Science ®Google Scholar
• Lexi-Drugs Online [Internet]. Hudson (OH): Lexicomp, Inc.; [cited 2022 Sep 23]. Available from: http://online.lexi.com.
   Google Scholar
• Marzano AV, Borghi A, Cugno M. Adverse drug reactions and organ damage: the skin. Eur J Intern Med. 2016;28:17–24. doi:10.1016/j.ejim.2015.11.017.
   PubMed Web of Science ®Google Scholar
• Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24(4):386–395. doi:10.1111/j.1529-8019.2011.01431.x.
   PubMed Web of Science ®Google Scholar
• Lupu I, Voiculescu N, Bacalbasa N, et al. Cutaneous complications of molecular targeted therapy used in oncology. J Med Life. 2016;9(1):19–25.
   PubMedGoogle Scholar
• Dreno B, Amici JM, Demessant-Flavigny AL, et al. The impact of acne, atopic dermatitis, skin toxicities and scars on quality of life and the importance of a holistic treatment approach. Clin Cosmet Investig Dermatol. 2021;14:623–632. doi:10.2147/CCID.S315846.
   PubMed Web of Science ®Google Scholar
• Radich JP. Treatment milestones in chronic myelogenous leukemia: stay the course or change therapy? J Natl Compr Canc Netw. 2015;13(5 Suppl):697–699. doi:10.6004/jnccn.2015.0207.
   PubMed Web of Science ®Google Scholar
• Delgado L, Giraudier S, Ortonne N, et al. Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia. J Am Acad Dermatol. 2013;69(5):839–840. doi:10.1016/j.jaad.2013.07.025.
   PubMed Web of Science ®Google Scholar
• Dahlén T, Edgren G, Ljungman P, et al. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study. Am J Hematol. 2022;97(4):421–430. doi:10.1002/ajh.26463.
   PubMed Web of Science ®Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services [INTERNET]. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.; [cited 2022 Mar 21]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_60.
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• McGuinness LA, Higgins JPT. Risk-of-bias visualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. doi:10.1002/jrsm.1411.
   PubMed Web of Science ®Google Scholar
• Del Pozzo-Magana BR, Liy-Wong C. Drugs and the skin: a concise review of cutaneous adverse drug reactions. Br J Clin Pharmacol. 2022. doi:10.1111/bcp.15490.
   Web of Science ®Google Scholar
• Coleman EL, Olamiju B, Leventhal JS. Potentially lifethreatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (review). Oncol Rep. 2021;45(3):891–898. doi:10.3892/or.2020.7911.
   PubMed Web of Science ®Google Scholar
• Salih J, Hilpert J, Placke T, et al. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer. 2010;127(9):2119–2128. doi:10.1002/ijc.25233.
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22(7):2214–2222. doi:10.1096/fj.07-105627.
   PubMed Web of Science ®Google Scholar
• Jung YS, Kim M, Lee JH, et al. Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Dermatol. 2016;174(2):456–458. doi:10.1111/bjd.14185.
   PubMed Web of Science ®Google Scholar
• Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002;117(3):620–622. doi:10.1046/j.1365-2141.2002.03499.x.
   PubMed Web of Science ®Google Scholar
• Lee H, Basso IN, Kim DDH. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol. 2021;113(5):632–641. doi:10.1007/s12185-021-03126-6.
   PubMed Web of Science ®Google Scholar
• Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;10:1862. doi:10.3389/fimmu.2019.01862.
   PubMed Web of Science ®Google Scholar
• Jung SH, Sun X, Ryu WS, et al. Topical administration of the pan‐src kinase inhibitors, dasatinib and LCB 03‐0110, prevents allergic contact dermatitis in mice. Br J Dermatol. 2013;168(1):112–119. doi:10.1111/bjd.12069.
   PubMed Web of Science ®Google Scholar
• Mahapatra M, Mishra P, Kumar R. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol. 2007;86(7):537–538. doi:10.1007/s00277-007-0265-y.
   PubMed Web of Science ®Google Scholar
• Hansen T, Little AJ, Miller JJ, et al. A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib. JAMA Dermatol. 2013;149(3):330–332. doi:10.1001/jamadermatol.2013.1375.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2(5):625–632. doi:10.1001/jamaoncol.2015.5932.
   PubMed Web of Science ®Google Scholar
• Pan P, Wang L, Wang Y, et al. Systematic review and Meta-Analysis of -New-Generation tyrosine kinase inhibitors versus imatinib for newly diagnosed chronic myeloid leukemia. Acta Haematol. 2020;143(3):204–216. doi:10.1159/000501537.
   PubMed Web of Science ®Google Scholar
• Bauer S, Buchanan S, Ryan I. Tyrosine kinase inhibitors for the treatment of Chronic-Phase chronic myeloid leukemia: long-Term patient care and management. J Adv Pract Oncol. 2016;7(1):42–54.
   PubMedGoogle Scholar
• Drucker AM, Wu S, Busam KJ, et al. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol. 2013;90(2):142–150. doi:10.1111/ejh.12052.
   PubMed Web of Science ®Google Scholar
• Sun W, Li J. Skin toxicities with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Cancer Invest. 2019;37(6):253–264. doi:10.1080/07357907.2019.1634089.
   PubMed Web of Science ®Google Scholar
• Manz KM, Fenchel K, Eilers A, et al. Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis. Adv Ther. 2020;37(2):730–744. doi:10.1007/s12325-019-01167-2.
   PubMed Web of Science ®Google Scholar
• Xue Y, Feng S, Li G, et al. Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis. Front Pharmacol. 2023;14:1160117. doi:10.3389/fphar.2023.1160117.
   PubMed Web of Science ®Google Scholar
• Ota S, Matsukawa T, Yamamoto S, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101(1):95–105. doi:10.1111/ejh.13081.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yin H, Chen L, et al. Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(2):e43–e49. doi:10.1016/j.clml.2019.12.001.
   PubMed Web of Science ®Google Scholar
• Belum VR, Washington C, Pratilas CA, et al. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. Pediatr Blood Cancer. 2015;62(5):798–806. doi:10.1002/pbc.25429.
   PubMed Web of Science ®Google Scholar
• Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898–3905. doi:10.1182/blood-2012-02-410688.
   PubMed Web of Science ®Google Scholar
• Nakamae H, Fujisawa S, Ogura M, et al. Dasatinib versus imatinib in japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105(6):792–804. doi:10.1007/s12185-017-2208-2.
   PubMed Web of Science ®Google Scholar
• Kizaki M, Takahashi N, Iriyama N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the new TARGET system. Int J Hematol. 2019;109(4):426–439. doi:10.1007/s12185-019-02613-1.
   PubMed Web of Science ®Google Scholar
• Bostan H, Toptas T, Tanrikulu FP, et al. Quality of life and symptom burden with first- and second-generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(12):836–842. doi:10.1016/j.clml.2020.08.009.
   PubMed Web of Science ®Google Scholar
• Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125(18):2771–2778. doi:10.1182/blood-2014-09-601674.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–453. doi:10.1038/s41375-020-01111-2.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486–3492. doi:10.1200/JCO.2011.38.7522.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–237. doi:10.1200/JCO.2017.74.7162.
   PubMed Web of Science ®Google Scholar
• Kwak JY, Kim SH, Oh SJ, et al. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res. 2017;23(23):7180–7188. doi:10.1158/1078-0432.CCR-17-0957.
   PubMed Web of Science ®Google Scholar